未经批准：描述双膦酸盐相关眼部副作用（BROSE）患者的临床特征。
UNASSIGNED：回顾了2009年1月至2019年12月期间所有BROSE患者的医疗记录。
未经批准：确定了9例BROSE患者。所有受试者均为女性。诊断时的中位年龄为69岁。双膦酸盐治疗的主要适应症是骨质疏松症（n=7），Paget骨病（n=1）和乳腺癌（n=1）。6例(66.67%)患者出现葡萄膜炎,1例（11%）上巩膜炎和2例（22%）眼眶炎症。在启动双膦酸盐后10天内发生了5起事件（55.5％），其余事件（44.44％）在2周至3年后发生。4例（44.44%）患者并发甲状腺疾病。发现潜在的甲状腺疾病或自身免疫之间存在关联。
未经证实：BROSE是双膦酸盐治疗的一种罕见并发症，在有自身免疫倾向的患者中更常见。
UNASSIGNED: To describe the clinical features of patients with bisphosphonate related ocular side effects (BROSE).
UNASSIGNED: The medical records of all patients with BROSE between January 2009 and December 2019 were reviewed.
UNASSIGNED: Nine cases with BROSE were identified. All subjects were female. Median age at diagnosis was of 69 years. The leading indication for bisphosphonate treatment was osteoporosis (n=7), Paget\'s disease of bone (n=1) and breast cancer (n=1). Six (66.67%) patients presented with uveitis, one (11%) episcleritis and two (22%) with orbital inflammation. Five events (55.5%) occurred within 10 days of initiating the bisphosphonate and the rest (44.44%) developed within 2 weeks to 3 years later. Four (44.44%) patients had concurrent thyroid disease. An association was found between underlying thyroid disease or autoimmunity.
UNASSIGNED: BROSE is an uncommon complication of bisphosphonate therapy occurring more frequently in patients with an autoimmune predisposition.
PDF(Sci-hub)